Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients

Addiction

Volumn 103, Issue 6, 2008, Pages 905-918

  Novick, David M ^a,b,c,d   Kreek, Mary Jeanne ^b  

^a Digestive Specialists Inc   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c KETTERING MEDICAL CENTER   (United States)

^d WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Antiviral therapy; Buprenorphine; Hepatitis C; Injection drug use; Liver transplantation; Medical care; Methadone maintenance

Indexed keywords

ANTIDEPRESSANT AGENT; BUPRENORPHINE; DIDANOSINE; METHADONE; NALOXONE; NEVIRAPINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACUTE PSYCHOSIS; ADDICTION; ANEMIA; ANTIBODY TITER; DEPRESSION; DRESS SYNDROME; DRUG DOSE REDUCTION; DRUG RESPONSE; FLU LIKE SYNDROME; GENOTYPE; HEALTH CARE QUALITY; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; IRRITABILITY; LIVER TRANSPLANTATION; MALAISE; MEDLINE; METHADONE TREATMENT; NEUTROPENIA; OPIATE ADDICTION; PSYCINFO; REVIEW; RISK FACTOR; SIDE EFFECT; SUICIDE; SUICIDE ATTEMPT; THROMBOCYTOPENIA;

ANALGESICS, OPIOID; ANTIVIRAL AGENTS; DELIVERY OF HEALTH CARE, INTEGRATED; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; METHADONE; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 43949117733     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2008.02188.x     Document Type: Review

References (152)

1. Novick D. M., Haverkos H. W., Teller D. W. The medically ill substance abuser. In : Lowinson J. M., Ruiz P., Millman R.B., Langrod J.G., editors. Substance Abuse: A Comprehensive Textbook, 3rd edn. Baltimore : Williams & Wilkins 1997, p. 534 50.
2. Kreek M. J. Rationale for maintenance pharmacotherapy of opiate dependence. In : O'Brien C. P., Jaffe J. H., editors. Addictive States. New York : Raven Press 1992 205 30.
3. Kreek M. J., LaForge S., Butelman E. Pharmacotherapy of addictions. Nat Rev Drug Discov 2002 1 : 710 26.
4. Kreek M. J. Long-term pharmacotherapy for opiate (primarily heroin) addiction: opioid antagonists and partial agonists. In : Schuster, C. R., Kuhar, M. J., editors. Pharmacological Aspects of Drug Dependence: Toward an Integrated Neurobehavioral Approach. Berlin : Springer-Verlag 1996, p. 563 98.
5. Buprenophine: an alternative to methadone. Med Lett Drug Ther 2003 45 : 13 5.
6. Sylvestre D. L. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002 67 : 117 23.
7. Schaefer M., Schmidt F., Folwaczny C., Lorenz R., Martin G., Schindlbeck N. et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003 37 : 443 51.
8. Van Thiel D. H., Anantharaju A., Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003 98 : 2281 8.
9. Mauss S., Berger F., Goelz J., Jacob B., Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004 40 : 120 4.
10. Sylvestre D. L., Litwin A. H., Clements B. J., Gourevitch M. N. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005 29 : 159 65.
11. Matthews G., Kronborg I. J., Dore G. J. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis 2005 40 : S325 9.
12. Robaeys G., Van Vlierberghe H., Mathei C., Van Ranst M., Bruckers L., Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol 2006 18 : 159 66.
13. Belfiori B., Chiodera A., Ciliegi P., Tosti A., Baldelli F., Stagni G. et al. Treatment for hepatitis C virus in injection drug users on opioid replacement therapy: a prospective multicentre study. Eur J Gastroenterol Hepatol 2007 19 : 731 2.
14. Krook A. L., Stokka D., Heger B., Nygaard E. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study. Eur Addict Res 2007 13 : 216 21.
15. Schaefer M., Hinzpeter A., Mohmand A., Janssen G., Pich M., Schwaiger M. et al. Hepatitis C treatment in 'difficult-to-treat' psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007 46 : 991 8.
16. Grebely J., Raffa J. D., Meagher C., Duncan F., Genoway K. A., Khara M. et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol 2007 22 : 1519 25.
17. Scheinmann R., Hagan H., Lelutiu-Weinberger C., Stern R., Des Jarlais D. C., Flom P. L. et al. Non-injection drug use and hepatitis C virus: a systematic review. Drug Alcohol Depend 2007 89 : 1 12.
18. Shepherd J., Brodin H., Cave C., Waugh N., Price A., Gabbay J. Pegylated interferon α-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004 8 : 1 140. Available at: http://www.hta.ac.uk (accessed 1 November 2007).
19. Robertson B., Myers G., Howard C., Brettin T., Bukh J., Gaschen B. et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. Arch Virol 1998 143 : 2493 503.
20. Farci P., Purcell R. H. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 2000 20 : 103 26.
21. Simmonds P., Holmes E. C., Cha T.-A., Chan S.-W., McOmish F., Irvine B. et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993 74 : 2391 9.
22. Haushofer A. C., Kopty C., Hauer R., Brunner H., Halbmayer W.-M. HCV genotypes and age distribution in patients of Vienna and surrounding areas. J Clin Virol 2001 20 : 41 7.
23. Lau J. Y. N., Davis G. L., Prescott L. E., Maertens G., Lindsay K. L., Qian K. et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Ann Intern Med 1996 124 : 868 76.
24. Matheï C., Wollants E., Verbeeck J., Van Ranst M., Robaeys G., Van Damme P. et al. Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours. Eur J Clin Microbiol Infect Dis 2005 24 : 514 22.
25. Armstrong G. L., Wasley A., Simard E. P., McQuillan G. M., Kuhnert W. L., Alter M. J. The prevalence of hepatitis C infection in the United States, 1999 through 2002. Ann Intern Med 2006 144 : 705 14.
26. Dienstag J. L. Hepatitis C: a bitter harvest. Ann Intern Med 2006 144 : 770 1.
27. Tahan V., Karaca C., Yildirim B., Bozbas A., Ozaras A., Demir K. et al. Sexual transmission of HCV between spouses. Am J Gastroenterol 2005 100 : 821 4.
28. McMahon J. M., Pouget E. R., Tortu S. Individual and couple-level risk factors for hepatitis C infection among heterosexual drug users: a multilevel dyadic analysis. J Infect Dis 2007 195 : 1572 81.
29. Hahn J. A. Sex, drugs, and hepatitis C virus. J Infect Dis 2007 195 : 1556 9.
30. Thomas D. L., Vlahov D., Solomon L., Cohn S., Taylor E., Garfein R. et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Balt) 1995 74 : 212 20.
31. Chetwynd J., Brunton C., Blank M., Plumridge E., Baldwin D. Hepatitis C seroprevalence amongst injecting drug users attending a methadone program. NZ Med J 1995 108 : 364 6.
32. Gabrielli C., Zannini A., Corradini R., Gafa S. Spread of hepatitis C virus among sexual partners of HCVAb positive intravenous drug users. J Infect 1994 29 : 17 22.
33. Soto B., Rodrigo L., Garcia-Bengoechea M., Sanchez-Quijano A., Riestra S., Arenas J. I. et al. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case: a multicentre study of 423 pairings. J Intern Med 1994 236 : 515 9.
34. Woodfield D. G., Harness M., Rix-Trott K. Hepatitis C virus infections in oral and injectable drug users. NZ Med J 1993 106 : 332 4.
35. Garfein R. S., Vlahov D., Galai N., Doherty M. C., Nelson K. E. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996 86 : 655 61.
36. Thiede H., Hagan H., Murrill C. S. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health: Bull NY Acad Med 2000 77 : 331 45.
37. Cook P. A., McVeigh J., Syed Q., Mutton K., Bellis M. A. Predictors of hepatitis B and C infection in injecting drug users both in and out of drug treatment. Addiction 2001 96 : 1787 97.
38. Rhodes T., Platt L., Maximova S., Koshkina E., Latishevskaya N., Hickman M. et al. Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. Addiction 2006 101 : 252 66.
39. Faye-White E., Garfein R. S., Brouwer K. C., Lozada R., Ramos R., Firestone-Cruz M. et al. Prevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the U.S. Salud Publica Mex 2007 49 : 165 72.
40. Peles E., Rados V., Adelson M. Characterization of former heroin addict patients with hepatitis C virus antibodies in a methadone maintenance treatment (MMT) clinic in Israel. Subst Use Misuse 2007 42 : 1477 84.
41. Thorpe L. E., Bailey S. L., Huo D., Monterroso E. R., Ouellet L. J. Injection-related risk behaviors in young urban and suburban injection drug users in Chicago (1997-1999). J Acquir Immune Defic Syndr 2001 27 : 71 8.
42. Miller C. L., Johnston C., Spittal P. M., Li K., LaLiberté N., Montaner J. S. G. et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002 36 : 737 42.
43. Novick D. M., Reagan K. J., Croxson T. S., Gelb A. M., Stenger R. J., Kreek M. J. Hepatitis C virus serology in parenteral drug users with chronic liver disease. Addiction 1997 92 : 167 71.
44. Des Jarlais D. C., Perlis T., Arasteh K., Torian L. V., Hagan H., Beatrice S. et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS 2005 19 : S20 5.
45. van de Laar T. J. W., Langendam M. W., Bruisten S. M., Welp E. A. E., Verhaest I., van Ameijden E. J. C. et al. Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands. J Med Virol 2005 77 : 509 18.
46. Chamot E., de Saussure P., Hirschel B., Deglon J. J., Perrin L. H. Incidence of hepatitis C, hepatitis B and HIV infections among drug users in a methadone-maintenance programme. AIDS 1992 6 : 430 1.
47. Selvey L. A., Denton M., Plant A. J. Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: factors influencing hepatitis C serostatus. Aust NZ J Public Health 1997 21 : 102 4.
48. Crofts N., Nigro L., Oman K., Stevenson E., Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction 1997 92 : 999 1005.
49. McCarthy J. J., Flynn N. Hepatitis C in methadone maintenance patients: prevalence and public policy implications. J Addict Dis 2001 20 : 19 31.
50. Piccolo P., Borg L., Lin A., Melia D., Ho A., Kreek M. J. Hepatitis C virus and human immunodeficiency virus-1 co-infection in former heroin addicts in methadone maintenance treatment. J Addict Dis 2002 21 : 55 66.
51. Novick D. M., Joseph H., Croxson T. S., Salsitz E. A., Wang G., Richman B. L. et al. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch Intern Med 1990 150 : 97 9.
52. Dole V. P. Implications of methadone maintenance for theories of narcotic addiction. JAMA 1988 260 : 3025 9.
53. Lauer G. M., Walker B. D. Hepatitis C virus infection. N Engl J Med 2001 345 : 41 52.
54. Lai M. E., Mazzoleni A. P., Argiolu F., De Virgilis S., Balestrieri A., Purcell R. H. et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994 343 : 388 90.
55. Farci P., Alter H. J., Shimoda A., Govindarajan S., Cheung L. C., Melpolder J. C. et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 1996 335 : 631 4.
56. Hoofnagle J. H. Course and outcome of hepatitis C. Hepatology 2002 36 : S21 9.
57. Wong W., Terrault N. Update on chronic hepatitis C. Clin Gastroenterol Hepatol 2005 3 : 507 20.
58. Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002 123 : 2082 99.
59. Kadam J. S., Talal A. H. Changing treatment paradigms: hepatitis C virus in HIV-infected patients. AIDS Patient Care STDS 2007 21 : 154 68.
60. Brown L. S., Kritz S. A., Goldsmith R. J., Bini E. J., Rotrosen J., Baker S. et al. Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat 2006 30 : 315 21.
61. Belle S. H., Beringer K. C., Detre K. M. Recent findings concerning liver transplantation in the United States. In : Cecka J. M., Terasaki P. I., editors. Clinical Transplants 1996, 1st edn. Los Angeles : UCLA Tissue Typing Laboratory 1997, p. 15 29.
62. Novick D. M., Enlow R. W., Gelb A. M., Stenger R. J., Fotino M., Winter J. W. et al. Hepatic cirrhosis in young adults: association with adolescent onset of alcohol and parenteral heroin abuse. Gut 1985 26 : 8 13.
63. Novick D. M., Stenger R. J., Gelb A. M., Most J., Yancovitz S. R., Kreek M. J. Chronic liver disease in abusers of alcohol and parenteral drugs: a report of 204 consecutive biopsy-proven cases. Alcohol Clin Exp Res 1986 10 : 500 5.
64. Pessione F., Degos F., Marcellin P., Duchatelle V., Njapoum C., Martinot-Peignoux M. et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998 27 : 1717 22.
65. Wiley T. E., McCarthy M., Breidi L., McCarthy M., Layden T. J. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998 28 : 805 9.
66. Safdar K., Schiff E. R. Alcohol and hepatitis C. Semin Liver Dis 2004 24 : 305 15.
67. Hutchinson S. J., Bird S. M., Goldberg D. J. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol 2005 3 : 1150 9.
68. Hezode C., Lonjon I., Roudot-Thoraval F., Pawlotsky J.-M., Zafrani E. S., Dhumeaux D. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C and specific influence of steatosis: a prospective study. Aliment Pharmacol Ther 2003 17 : 1031 7.
69. Chang A., Skole K., Gautam M., Schmutz J., Black M., Thomas R. et al. The impact of past alcohol use on treatment response rates in patients with chronic hepatitis C. Aliment Pharmacol Ther 2005 22 : 701 6.
70. Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., Albrecht J. Rates and risk factors of liver fibrosis in patients with chronic hepatitis C. J Hepatol 2001 34 : 730 9.
71. Sterling R. K., Sulkowski M. S. Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection. Semin Liver Dis 2004 24 : 61 8.
72. Glue P., Fang J. W. S., Rouzier-Panis R., Raffanel C., Sabo R., Gupta S. K. et al. Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000 68 : 556 67.
73. Yee H. S., Currie S. L., Darling J. M., Wright T. L. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 2006 101 : 2360 78.
74. Manns M. P., McHutchison J. G., Gordon S. C., Rustgi V. K., Shiffman M., Reindollar R. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 65.
75. Fried M. W., Shiffman M. L., Reddy K. R., Smith C., Marinos G., Gonçales F. L. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 82.
76. Zeuzem S., Feinman S. V., Rasenack J., Heathcote E. J., Lai M.-Y., Gane E. et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000 343 : 1666 72.
77. Heathcote E. J., Shiffman M. L., Cooksley W. G. E., Dusheiko G. M., Lee S. S., Balart L. et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000 343 : 1673 80.
78. Poynard T., McHutchison J., Manns M., Trepo C., Lindsay K., Goodman Z. et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002 122 : 1303 13.
79. Batts K. P., Ludwig J. Chronic hepatitis: an update on terminology and reporting. Am J Surg Pathol 1995 19 : 1409 17.
80. Hadziyannis S. J., Sette H., Morgan T. J., Balan V., Diago M., Marcellin P. et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004 140 : 346 55.
81. Berg T., von Wagner M., Nasser S., Sarrazin C., Heintges T., Gerlach T. et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006 130 : 1086 97.
82. Sánchez-Tapias J. M., Diago M., Escartín P., Enríquez J., Romero-Gómez M., Bárcena R. et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006 131 : 451 60.
83. Fried M. W. Side effects of therapy of hepatitis C and their management. Hepatology 2002 36 : S237 4.
84. Sulkowski M., Wright T., Rossi S., Arora S., Lamb M., Wang K. et al. Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. Clin Pharmacol Ther 2005 77 : 214 24.
85. Berk S. I., Litwin A. H., Arnsten J. H., Du E., Soloway I., Gourevitch M. N. Effects of pegylated interferon alfa-2b on the pharmacokinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment. Clin Ther 2007 29 : 131 8.
86. Gupta S. K., Sellers E., Somoza E., Angles L., Kolz K., Cutler D. L. The effect of multiple doses of peginterferon alfa-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. J Clin Pharmacol 2007 47 : 604 12.
87. Dore G. J., Thomas D. L. Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection. Semin Liver Dis 2005 25 : 18 32.
88. Vento S., Garofano T., Renzini C., Cainelli F., Casali F., Ghironzi G. et al. Fulminant hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 1998 338 : 286 90.
89. Deterding K., Tegtmeyer B., Cornberg M., Hadem J., Potthoff A., Böker K. H. W. et al. Hepatitis A virus infection suppresses hepatitis C replication and may lead to clearance of HCV. J Hepatol 2006 45 : 770 8.
90. Bart G., Piccolo P., Zhang L., Jacobson I., Schaefer R., Kreek M. J. Markers for hepatitis A, B, and C in methadone maintained patients: an unexpectedly high coinfection with silent hepatitis B. Addiction 2008 103 : 681 6.
91. Dalgard O., Bjøro K., Hellum K., Myrvang B., Skaug K., Gutigard B. et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002 8 : 45 9.
92. Backmund M., Meyer K., Edlin B. R. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004 39 : 1540 3.
93. Schaefer M., Heinz A., Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 2004 99 : 1167 75.
94. Robaeys G., Buntinx F. Treatment of hepatitis C viral infections in substance abusers. Acta Gastroenterol Belg 2005 68 : 55 67.
95. Sulkowski M. S., Moore R. D., Mehta S. H., Chaisson R. E., Thomas D. L. Hepatitis C and progression of HIV disease. JAMA 2002 288 : 199 206.
96. Sulkowski M. S., Thomas D. L. Hepatitis C in the HIV-infected person. Ann Intern Med 2003 138 : 197 207.
97. George S. L., Gebhardt J., Klinzman D., Foster M. B., Patrick K. D., Schmidt W. N. et al. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr 2002 31 : 154 62.
98. Serfaty L., Costagliola D., Wendrum D., Picard O., Meyohas M.-C., Girard P.-M. et al. Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a case-control study. AIDS 2001 15 : 2011 6.
99. Di Martino V., Rufat P., Boyer N., Renard P., Degos F., Martinot-Peignoux M. et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001 34 : 1193 9.
100. Bruno R., Sacchi P., Puoti M., Soriano V., Filice G. HCV chronic hepatitis in patients with HIV: clinical management issues. Am J Gastroenterol 2002 97 : 1598 606.
101. Bica I., McGovern B., Dhar R., Stone D., McGowan K., Scheib R. et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001 32 : 492 7.
102. Dybul M., Fauci A., Bartlett J. G., Kaplan J. E., Pau A. K. Guidelines for using antiviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002 137 : 381 433.
103. Montessori V., Harris M., Montaner J. S. G. Hepatotoxicity of nucleoside reverse transcriptase inhibitors. Semin Liver Dis 2003 23 : 167 71.
104. Savès M., Raffi F., Clevenburgh P., Marchou B., Waldner-Combernoux A., Morlat P. et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2000 44 : 3451 5.
105. Sherman K. E., Peters M., Koziel M. J. HIV and liver disease forum: conference proceedings. Hepatology 2007 45 : 1566 77.
106. McCance-Katz E. F. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiviral agents. Clin Infect Dis 2005 41 : S89 95.
107. Bruce R. D., Altice F. L., Gourevitch M. N., Friedland G. H. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr 2006 41 : 563 72.
108. Maas B. M., Kerr T., Fairbairn N., Montaner J., Wood E. Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence. Expert Opin Drug Metab Toxicol 2006 2 : 533 43.
109. Torriani F. J., Rodriquez-Torres M., Rockstroh J. K., Lissen E., Gonzalez-García J., Lazzarin A. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New Engl J Med 2004 351 : 438 50.
110. Chung R. T., Anderson J., Volberding P., Robbins G. K., Liu T., Sherman K. E. et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004 351 : 451 9.
111. Carrat F., Bani-Sadr F., Pol S., Rosenthal E., Lunel-Fabiani F., Benzekri A. et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004 292 : 2839 48.
112. Manns M. R., Wedemeyer H. Treatment of hepatitis C in HIV-infected patients: significant progress but not the final step. JAMA 2004 292 : 2909 13.
113. Koziel M. J., Peters M. G. Viral hepatitis in HIV infection. N Engl J Med 2007 356 : 1445 54.
114. Palepu A., Tyndall M. W., Joy R., Kerr T., Wood E., Press N. et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected drug users: the role of methadone maintenance therapy. Drug Alcohol Depend 2006 84 : 188 94.
115. Gonzalez S. A., Talal A. H. Hepatitis C virus in human immunodeficiency virus-infected individuals: an emerging comorbidity with significant implications. Semin Liver Dis 2003 23 : 149 66.
116. Baba M., Pauwels R., Balzarini J., Herdewijn P., De Clercq E., Desmyter J. Ribavirin antagonizes inhibitory effects of pymimidine 2′,3′- dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother 1987 31 : 1613 7.
117. Koch M., Banys P. Liver transplantation and opioid dependence. JAMA 2001 285 : 1056 8.
118. Koch M., Banys P. Methadone is a medication, not an addiction. Liver Transpl 2002 8 : 783 6.
119. Di Martini A., Weinrieb R. Liver transplantation for methadone-maintained opiate dependents: making the case for cautious optimism. Am J Transpl 2003 3 : 1183 4.
120. Joseph H., Stancliff S., Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med 2000 67 : 347 64.
121. Kanchana T. P., Kaul V., Manzarbeitia C., Reich D. J., Hails K. C., Munoz S. J. et al. Liver transplantation for patients on methadone maintenance. Liver Transpl 2002 8 : 778 82.
122. Liu L. U., Schiano T. D., Lau N., O'Rourke M., Min A. D., Sigal S. H. et al. Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation. Am J Transpl 2003 3 : 1273 7.
123. Weinrieb R. M., Barnett R., Lynch K. G., DePiano M., Atanda A., Olthoff K. M. A matched comparison study of medical and psychiatric complications and anesthesia and analgesia requirements in methadone-maintained liver transplant recipients. Liver Transpl 2004 10 : 97 106.
124. Hancock M. M., Prosser C. C., Ransibrahmanakul K., Lester L., Craemer E., Bourgeois J. A. et al. Liver transplant and hepatitis C in methadone maintenance therapy: a case report. Subst Abuse Treat Prevent Policy 2007 2 : 5. Available at: http://www.substanceabusepolicy.com.content/2/1/5 (accessed 18 June 2007).
125. Terrault N. A., Berenguer M. Treating hepatitis C in liver transplant recipients. Liver Transpl 2006 12 : 1192 204.
126. Kotlyar D. S., Campbell M. S., Reddy K. R. Recurrence of diseases following orthotopic liver transplantation. Am J Gastroenterol 2006 101 : 1370 8.
127. Miró J. M., Torre-Cisnero J., Moreno A., Tuset M., Quereda C., Laguno M. et al. GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March 2005). Enferm Infecc Microbiol Clin 2005 23 : 353 62.
128. Miró J. M., Laguno M., Moreno A., Rimola A., Hospital Clinic OLT in HIV Working Group. Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)? J Hepatol 2006 44 : S140 5.
129. Sharma P., Marrero J. A., Fontana R. J., Greenson J. K., Conjeevaram H., Su G. L. et al. Sustained virological response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007 13 : 1100 8.
130. McCashland T., Watt K., Lyden E., Adams L., Charlton M., Smith A. D. et al. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl 2007 13 : 1246 53.
131. Dole V. P., Nyswander M. E., Kreek M. J. Narcotic blockade. Arch Intern Med 1966 118 : 304 9.
132. Kreek M. J., Dodes L., Kane S., Knobler J., Martin R. Long-term methadone maintenance therapy: effect on liver function. Ann Intern Med 1972 77 : 598 602.
133. Novick D. M., Richman B. L., Friedman J. M., Friedman J. E., Fried C., Wilson J. P. et al. The medical status of methadone maintenance patients in treatment for 11-18 years. Drug Alcohol Depend 1993 33 : 235 45.
134. Novick D. M., Ochshorn M., Ghali V., Croxson T. S., Mercer W. D., Chiorazzi N. et al. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J Pharmacol Exp Ther 1989 250 : 606 10.
135. Novick D. M., Kreek M. J., Fanizza A. M., Yancovitz S. R., Gelb A. M., Stenger R. J. Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther 1981 30 : 353 62.
136. Novick D. M., Kreek M. J., Arns P. A., Lau L. L., Yancovitz S. R., Gelb A. M. Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients. Alcohol Clin Exp Res 1985 9 : 349 54.
137. Peles E., Bodner G., Kreek M. J., Rados V., Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients - a cross-sectional study. Addiction 2007 102 : 289 300.
138. Sullivan L. E., Chawarski M., O'Connor P. G., Schottenfeld R. S., Fiellin D. A. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend 2005 79 : 113 6.
139. Stein M. D., Maksad J., Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend 2001 61 : 211 5.
140. Edlin B. R. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002 36 : S210 9.
141. Kresina T. F., Seeff L. B., Francis H. Hepatitis C infection and injection drug use: the role of hepatologists in evolving treatment efforts. Hepatology 2004 40 : 516 9.
142. Sylvestre D. L., Loftis J. M., Hauser P., Genser S., Cesari H., Borek N. et al. Co-occurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health: Bull NY Acad Med 2004 81 : 719 34.
143. Edlin B. R., Kresina T. F., Raymond D. B., Carden M. R., Gourevitch M. N., Rich J. D. et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005 40 : S276 85.
144. Taylor L. E. Delivering care to injection drug users coinfected with HIV and hepatitis C. Clin Infect Dis 2005 40 : S355 61.
145. Strauss S. M., Astone-Twerell J., Munoz-Plaza C. E., Des Jarlais D. C., Gwadz M., Hagan H. et al. Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Serv Res 2007 7 : 39. Available at: http://www.biomedcentral.com/1472- 6963/7/39 (accessed 18 June 2007).
146. World health Organization. Substitution Maintenance Therapy in the Management of Opioid Dependence and HIV/AIDS Prevention: Position Paper. Geneva : World Health Organization, United Nations Office on Drugs and Crime, UNAIDS 2004. Available at: http://www.who.int/substance_abuse (accessed 1 November 2007).
147. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. JAMA 1998 280 : 1936 43.
148. Hallinan R., Byrne A., Agho K., Dore G. J. Referral for chronic hepatitis C treatment from a drug dependency setting. Drug Alcohol Depend 2007 88 : 49 53.
149. Moirand R., Bilodeau M., Brissette S., Bruneau J. Determinants of antiviral treatment initiation in a hepatitis C-infected population benefiting from universal health care coverage. Can J Gastroenterol 2007 21 : 355 61.
150. Sylvestre D. L., Clements B. J. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 2007 19 : 741 7.
151. Watson B., Conigrave K. M., Wallace C., Whitfield J. B., Wurst F., Haber P. S. Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment. Drug Alcohol Rev 2007 26 : 231 9.
152. Sheerin I. G., Green F. T., Sellman J. D. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand? Drug Alcohol Rev 2004 23 : 261 72.